<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358264</url>
  </required_header>
  <id_info>
    <org_study_id>Pharmacology-Medicine-UJ</org_study_id>
    <nct_id>NCT03358264</nct_id>
  </id_info>
  <brief_title>Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes</brief_title>
  <official_title>Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Type II Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jordan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arginase has recently been implicated in an array of vascular conditions including
      atherosclerosis , hypertension and vascular complication of diabetes. In this study we will
      determine of L-citrulline; a natural amino acid that is known to have inhibitory effects on
      arginase activity, on vascular function in type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascular dysfunction is a major cause of morbidity and mortality in diabetic patients. The
      pathological process is characterized by impaired endothelial cell production of the
      vasodilator and antiplatelet adhesion factor nitric oxide (NO) and/or decreased NO
      bioavailability. NO is a major regulator of vascular tone and integrity. In endothelial
      cells, NO is produced by activity of endothelial NO synthase (eNOS) on its substrate
      L-arginine. Reduced availability of L-arginine to eNOS has been implicated in vascular
      dysfunction in diabetes and a variety of other disease conditions. Arginase, which
      metabolizes L-arginine to urea and ornithine, competes directly with NOS for L-arginine.
      Hence increases in arginase activity can decrease tissue and cellular arginine levels,
      reducing its availability to eNOS and decreasing No production. During diabetes, elevated
      levels of arginase can compete with NOS for available arginine thus reducing vascular NO. We
      have recently shown that arginase activity is elevated in diabetes. In this proposal we
      implement a method of flow mediate dilation (FMD) to assess vascular function in diabetic
      patients. We will study the relation of our vascular function findings with arginase activity
      levels. We propose that arginase activity measurements could be novel marker of vascular
      dysfunction in diabetes. The effect of the natural amino acid supplements (L-citrulline) on
      levels of arginase activity in diabetic patients and vascular function will also be studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arginase activity</measure>
    <time_frame>1 month</time_frame>
    <description>Levels of arginase activity enzyme will be measured in plasma in subjects before and after l-citrulline supplementation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>1 month</time_frame>
    <description>forearm vascular function will be assessed by flow mediated dilation of brachial blood vessels before and after L-citrulline supplementation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to type 2 diabetic patients with HbA1c&gt;6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to non-diabetic healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-citrulline</intervention_name>
    <description>Amino acid supplement</description>
    <arm_group_label>Type 2 diabetic patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabetes Diabetic state: HbA1c&gt;6

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alia Shatanawi, PhD, DDS</last_name>
    <phone>+96265355000</phone>
    <phone_ext>23458</phone_ext>
    <email>a.shatanawi@ju.edu.jo</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Munir N Gharaibeh, PhD, MD</last_name>
    <phone>96265355000</phone>
    <phone_ext>23456</phone_ext>
    <email>mgharaib@ju.edu.jo</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Jordan</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alia Shatanawi, PhD, DDS</last_name>
      <phone>+96265355000</phone>
      <phone_ext>23458</phone_ext>
      <email>a.shatanawi@ju.edu.jo</email>
    </contact>
    <contact_backup>
      <last_name>Munir N Gharaibeh, PhD, MD</last_name>
      <phone>+96265355000</phone>
      <phone_ext>23456</phone_ext>
      <email>mgharaib@ju.edu.jo</email>
    </contact_backup>
    <investigator>
      <last_name>Munther S Momani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alia Shatanawi, PhD, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <reference>
    <citation>Shatanawi A, Momani, MS. Plasma arginase activity is elevated in type 2 diabetic patients. Biomedical Research-India 28(9): 4102-4106, 2017</citation>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2017</study_first_submitted>
  <study_first_submitted_qc>November 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <last_update_submitted>November 26, 2017</last_update_submitted>
  <last_update_submitted_qc>November 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Alia Shatanawi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Vascular dysfunction, L-citrulline, arginase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

